CervoMed to Participate in the BIO CEO and Investor Conference
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for […]
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), […]
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical […]
Synchronoss to Unveil New Version of AI-Powered Personal Cloud Platform at Mobile World Congress
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ: SNCR), a global leader […]
Worksport Announces SOLIS Solar Cover Availability for Ford F-150 Lightning, Pioneering Sustainable Off-Grid Energy Solutions for EV Pickup Trucks
West Seneca, New York, Feb. 21, 2024 (GLOBE NEWSWIRE) — Worksport Ltd. (Nasdaq: WKSP;) (“Worksport” or the “Company”) announces that […]
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping […]
Phillips Edison & Company to Host PECO GROW Update for Financial Advisors and Retail Investors on February 29
CINCINNATI, Feb. 21, 2024 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of […]
Stock Yards Bancorp Declares Quarterly Cash Dividend of $0.30 Per Common Share
LOUISVILLE, Ky., Feb. 21, 2024 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank […]
Verisk Reports Fourth-Quarter 2023 and Full-Year 2023 Financial Results
Consolidated revenues were $677.2 million, up 7.4% and up 6.0% on an organic constant currency (OCC) basis for the fourth quarter of 2023. Prior year [...]
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug […]
